keyword
MENU ▼
Read by QxMD icon Read
search

breast neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28097443/axillary-ultrasound-before-neoadjuvant-chemotherapy-for-breast-cancer-don-t-discount-the-benefits-yet
#1
EDITORIAL
Theresa L Schwartz, Julie A Margenthaler
No abstract text is available yet for this article.
January 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28093280/metronomics-in-the-neoadjuvant-and-adjuvant-treatment-of-breast-cancer
#2
Elisabetta Munzone, Marco Colleoni
The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments...
January 13, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28089283/myc-amplification-as-a-predictive-factor-of-complete-pathologic-response-to-docetaxel-based-neoadjuvant-chemotherapy-for-breast-cancer
#3
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28088868/prognostic-values-of-ki-67-in-neoadjuvant-setting-for-breast-cancer-a-systematic-review-and-meta-analysis
#4
Lun Li, Dongdong Han, Xiaowei Wang, Quan Wang, Jinhui Tian, Jia Yao, Liqin Yuan, Ke Qian, Qiongyan Zou, Wenjun Yi, Enxiang Zhou, Kehu Yang
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28087643/tumor-brca1-reversion-mutation-arising-during-neoadjuvant-platinum-based-chemotherapy-in-triple-negative-breast-cancer-is-associated-with-therapy-resistance
#5
Anosheh Afghahi, Kirsten M Timms, Shaveta Vinayak, Kristin C Jensen, Allison W Kurian, Robert W Carlson, Pei-Jen Chang, Elizabeth A Schackmann, Anne-Renee Hartman, James M Ford, Melinda L Telli
BACKGROUND: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. We evaluated this mechanism of resistance in newly diagnosed BRCA1/2-mutant breast cancer patients with poor response to neoadjuvant platinum-based therapy. METHODS: PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and iniparib in patients with stage I-IIIA triple-negative or BRCA1/2 mutation-associated breast cancer (n=80)...
January 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28087389/evaluation-of-local-oncologic-safety-in-nipple-areola-complex-sparing-mastectomy-after-primary-chemotherapy-a-propensity-score-matched-study
#6
Roberto Agresti, Marco Sandri, Massimiliano Gennaro, Giulia Bianchi, Ilaria Maugeri, Mario Rampa, Giuseppe Capri, Maria Luisa Carcangiu, Giovanna Trecate, Egidio Riggio, Laura Lozza, Filippo de Braud
BACKGROUND: Nipple-areola complex-sparing mastectomy (NSM), extending the concept of skin-sparing mastectomy, allows for the provision of a better cosmetic result. Large operable T2-T3 breast cancer might theoretically appear suitable for this surgical option as an alternative to conventional mastectomy or breast-conserving surgery, when a good response to primary chemotherapy has been achieved. PATIENTS AND METHODS: From January 2009 to May 2013, 422 patients with invasive breast cancer were progressively accrued to NSM...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28078854/changes-of-expression-of-estrogen-and-progestrone-receptors-human-epithelial-growth-factor-receptor-2-and-ki-67-after-neoadjuvant-chemotherapy-in-the-treatment-of-breast-cancer
#7
M L Li, Y Dong, S L Luan, Z H Zhao, F L Ning
Recent studies suggest that the development and prognosis of breast cancer is in close correlation to molecular subtype of breast cancer. Neoadjuvant chemotherapy has been extensively applied in the treatment of local breast cancer in advanced stage. In order to verify the correlation between expression changes of estrogen receptor, progestrone receptor, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy and neoadjuvant chemotherapy, we studied 120 patients with stage IIAIIIC breast cancer who underwent neoadjuvant chemotherapy in Binzhou Medical University Hospital, Shandong, China from February 2011 to February 2015...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28075166/the-predictive-value-of-ki-67-before-neoadjuvant-chemotherapy-for-breast-cancer-a-systematic-review-and-meta-analysis
#8
Xianyu Chen, Chao He, Dongdong Han, Meirong Zhou, Quan Wang, Jinhui Tian, Lun Li, Feng Xu, Enxiang Zhou, Kehu Yang
AIM: To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients. METHODS: PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software. RESULTS: High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR(+), HER2(+) and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67...
January 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28073896/patient-specific-circulating-tumor-dna-detection-during-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#9
Francesca Riva, Francois-Clement Bidard, Alexandre Houy, Adrien Saliou, Jordan Madic, Aurore Rampanou, Caroline Hego, Maud Milder, Paul Cottu, Marie-Paule Sablin, Anne Vincent-Salomon, Olivier Lantz, Marc-Henri Stern, Charlotte Proudhon, Jean-Yves Pierga
BACKGROUND: In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery. METHODS: Ten milliliters of plasma were collected at 4 time points: before NCT; after 1 cycle; before surgery; after surgery. Customized droplet digital PCR (ddPCR) assays were used to track tumor protein p53 (TP53) mutations previously characterized in tumor tissue by massively parallel sequencing...
January 10, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28072617/evaluation-of-the-response-to-breast-cancer-neoadjuvant-chemotherapy-using-18f-fdg-positron-emission-mammography-compared-with-whole-body-18f-fdg-pet-a-prospective-observational-study
#10
Mutsumi Noritake, Kazutaka Narui, Tomohiro Kaneta, Sadatoshi Sugae, Kentaro Sakamaki, Tomio Inoue, Takashi Ishikawa
PURPOSE: The aim of this study was to assess therapeutic response to breast cancer neoadjuvant chemotherapy (NAC) by F-FDG positron emission mammography (PEM) compared with that to whole-body F-FDG PET (WBPET). METHODS: Twenty patients underwent WBPET and PEM 3 times: the first time was before NAC, the second time was after 2 courses of NAC, and the third time was after all courses of NAC. A pathological complete response (pCR) was defined as no evidence of residual invasive cancer with or without ductal carcinoma in situ...
January 9, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28071613/clinical-and-pathologic-response-following-taxane-based-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer-patients-in-a-tertiary-care-centre-in-india
#11
Masillamany Sivasanker, S C Sistla, S Ali Manwar, S Vivekanandam
BACKGROUND: Neoadjuvant chemotherapy has become the standard recommendation in the management of patients with locally advanced breast cancer. At present anthracycline based regimen such as CAF (cyclophosphamide, adriamycin and 5-FU) is widely used in clinical practice. The introduction of taxanes has revolutionized this field because of superior results. AIMS AND OBJECTIVES: This study is designed to compare the efficacy of paclitaxel plus doxorubicin regimen and CAF (cyclophosphamide, doxorubicin and 5-fluorouracil) regimen as neoadjuvant treatment of locally advanced breast cancer and to compare their toxicity profiles and also to correlate the hormonal receptor status in predicting response to the NACT...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28066808/effect-of-mr-imaging-contrast-thresholds-on-prediction-of-neoadjuvant-chemotherapy-response-in-breast-cancer-subtypes-a-subgroup-analysis-of-the-acrin-6657-i-spy-1-trial
#12
Wen Li, Vignesh Arasu, David C Newitt, Ella F Jones, Lisa Wilmes, Jessica Gibbs, John Kornak, Bonnie N Joe, Laura J Esserman, Nola M Hylton
Functional tumor volume (FTV) measurements by dynamic contrast-enhanced magnetic resonance imaging can predict treatment outcomes for women receiving neoadjuvant chemotherapy for breast cancer. Here, we explore whether the contrast thresholds used to define FTV could be adjusted by breast cancer subtype to improve predictive performance. Absolute FTV and percent change in FTV (ΔFTV) at sequential time-points during treatment were calculated and investigated as predictors of pathologic complete response at surgery...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28065399/oncologic-safety-of-immediate-breast-reconstruction-in-breast-cancer-patients-who-underwent-neoadjuvant-chemotherapy-short-term-outcomes-of-a-matched-case-control-study
#13
Jai Min Ryu, Sungmin Park, Hyun-June Paik, Seok Jin Nam, Seok Won Kim, Se Kyung Lee, Jonghan Yu, Soo Youn Bae, Isaac Kim, Sa Ik Bang, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon, Jeong Eon Lee
INTRODUCTION: Although the indication for immediate breast reconstruction (IBR) after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) has been expanded, IBR after neoadjuvant chemotherapy (NACT) is still controversial. We conducted retrospective matched case-control study to analyze oncologic outcomes between patients who underwent TM only and those who underwent IBR after SSM or NSM after NACT. PATIENTS AND METHODS: A retrospective review of breast cancer patients who underwent IBR after SSM or NSM after NACT between 2008 and 2015 at a single center was conducted...
October 27, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28064072/long-term-outcome-of-breast-cancer-patients-with-pathologic-n3a-lymph-node-stage
#14
Antonino Grassadonia, Patrizia Vici, Teresa Gamucci, Luca Moscetti, Laura Pizzuti, Lucia Mentuccia, Laura Iezzi, Maria Teresa Scognamiglio, Marinella Zilli, Jamara Giampietro, Vincenzo Graziano, Clara Natoli, Nicola Tinari
PURPOSE: To evaluate factors influencing the long-term outcome of patients presenting with 10 or more metastatic axillary lymph nodes (pN3a) after surgery for primary breast cancer. METHOD: Between January 1990 and December 2015, a total of 130 patients with pN3a breast cancer at surgery were identified in our Institutions and included in the study. Twenty-nine of them (22.3%) received neoadjuvant chemotherapy. The Multivariate Cox proportional hazards model was used to determine independent prognostic factors associated with DFS and OS...
January 5, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28063331/pcr-rates-in-patients-with-bilateral-breast-cancer-after-neoadjuvant-anthracycline-taxane-based-chemotherapy-a-retrospective-pooled-analysis-of-individual-patients-data-of-four-german-neoadjuvant-trials
#15
Mattea Reinisch, Jens Huober, Gunter von Minckwitz, Jens-Uwe Blohmer, Carsten Denkert, Claus Hanusch, Christian Jackisch, Sherko Kümmel, Andreas Schneeweiss, Kerstin Rhiem, Bianca Lederer, Michael Untch, Valentina Nekljudova V, Sibylle Loibl
PURPOSE: Patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and little is known about the response and outcome of BBC to neoadjuvant chemotherapy compared to unilateral BC (UBC). METHODS: We prospectively captured the information on patients with BBC in our database treated within four neoadjuvant chemotherapy trials and collected retrospectively the rate of pathological complete response (pCR) defined as ypT0 ypN0, ypT0/is ypN0, ypT0 ypNX, clinical and histologic parameters...
January 4, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28062931/fewer-reoperations-after-lumpectomy-for-breast-cancer-with-neoadjuvant-rather-than-adjuvant-chemotherapy-a-report-from-the-national-cancer-database
#16
Jeffrey Landercasper, Barbara Bennie, Benjamin M Parsons, Leah L Dietrich, Caprice C Greenberg, Lee G Wilke, Jared H Linebarger
BACKGROUND: Reoperations occur frequently after initial lumpectomy for breast cancer. The authors hypothesized that the receipt of neoadjuvant chemotherapy (NAC) is associated with fewer reoperations. METHODS: The association between timing of chemotherapy and reoperation rates (ROR) after lumpectomy was investigated for patients with stages 1-3 breast cancer in the National Cancer Database (NCDB) from 2010 to 2013 by multivariable logistic regression modeling. Then propensity score-matching was performed...
January 6, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28061451/nanoparticle-albumin-bound-paclitaxel-as-neoadjuvant-chemotherapy-of-breast-cancer-a-systematic-review-and-meta-analysis
#17
REVIEW
Yu Zong, Jiayi Wu, Kunwei Shen
BACKGROUND: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain. METHODS: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28058550/do-calcifications-seen-on-mammography-after-neoadjuvant-chemotherapy-for-breast-cancer-always-need-to-be-excised
#18
Yara Feliciano, Anita Mamtani, Monica Morrow, Michelle M Stempel, Sujata Patil, Maxine S Jochelson
BACKGROUND: This study aimed to determine the relationship between mammographic calcifications and magnetic resonance imaging (MRI) tumoral enhancement before and after neoadjuvant chemotherapy (NAC) and to assess the impact of these findings on surgical management. METHODS: This Institutional Review Board-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant retrospective study involved breast cancer patients who underwent NAC between 2009 and 2015...
January 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28057031/-18-fdg-pet-ct-for-predicting-the-outcome-in-er-her2-breast-cancer-patients-comparison-of-clinicopathological-parameters-and-pet-image-derived-indices-including-tumor-texture-analysis
#19
David Groheux, Antoine Martineau, Luis Teixeira, Marc Espié, Patricia de Cremoux, Philippe Bertheau, Pascal Merlet, Charles Lemarignier
BACKGROUND: This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)FDG-PET/CT) indices, including textural features, to predict event-free survival (EFS) in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced breast cancer (BC) patients. METHODS: FDG-PET/CT indices and clinicopathological parameters were assessed before neoadjuvant chemotherapy (NAC)...
January 5, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28055977/risk-factors-of-locoregional-relapse-in-locally-advanced-breast-cancer-treated-with-neoadjuvant-chemotherapy-following-mastectomy-and-radiotherapy
#20
Liang Huang, Sheng Chen, Wentao T Yang, Zhiming Shao
We seek to investigate the prognostic factors that could possibly increase the locoregional recurrence of breast cancer patients who do not achieve pathological complete response after neoadjuvant chemotherapy, and to build a prognostic nomogram to predict patients' outcome. The retrospective analysis included 510 patients who had received neoadjuvant chemotherapy followed by surgery and radiotherapy. 62 locoregional events occurred after a median 61 months of follow-up. The five-year cumulative incidence of local recurrence and regional recurrence were 8...
December 31, 2016: Oncotarget
keyword
keyword
55508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"